Faculty profile

Elizabeth Tullis

Back to faculty

ProfessorDepartment of MedicineUniversity of Toronto

Elizabeth Tullis

Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
21 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,708

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.
Respiratory medicine · 2026
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.
American journal of respiratory and critical care medicine · 2026
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
The Lancet Respiratory Medicine · 2025

All 61 publications

61 publications.

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.

Kharraz R, Tullis E, Sykes J, Ma X, Sandhu A, Gryz Z, Shulman Y, Tam J, Love A, Ratjen F, Rayment JH, Quon BS, Stephenson AL

Respiratory medicine2026

DOI: 10.1016/j.rmed.2026.108827 PMID: 42019640

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.

Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, Mall MA, Fajac I

American journal of respiratory and critical care medicine2026

DOI: 10.1093/ajrccm/aamaf001 PMID: 41738096

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, Lena P. Thia, Philip J. Robinson, Pornchai Tirakitsoontorn, Bonnie W. Ramsey, Marcus Alexander Mall, Jennifer L. Taylor‐Cousar, Edward F. McKone, Elizabeth D. Tullis, Danieli B. Salinas, Jesse Zhu, Yangbiao Chen, Violeta Rodriguez‐Romero, Patrick R. Sosnay, Gwyneth A. Davies, Gary McPhail, Karen McCoy, Erica Roesch, Daniel Weiner, Carlos Milla, Jessica Pittman, Rachel Linnemann, Anne Stone, Hugo Escobar, James Chmiel, Fadel Ruiz, Jonathan Gaffin, et al. (51 authors)

The Lancet Respiratory Medicine202556 citationsOpen Access

DOI: 10.1016/s2213-2600(24)00407-7 PMID: 39756425

Exploring the effects of pulmonary rehabilitation and its determinants in lung transplant candidates with cystic fibrosis.

Nicholson JM, Goldstein R, Nourouzpour S, Elangeswaran B, Munawar M, Wickerson L, Keshavjee S, Tullis E, Chaparro C, Rozenberg D

Respiratory medicine20252 citationsOpen Access

DOI: 10.1016/j.rmed.2025.107982 PMID: 39921065

A Multicenter Retrospective Study Evaluating IL-5-Targeted Biologic Therapies for the Treatment of Asthma and Allergic Bronchopulmonary Aspergillosis in Adults With Cystic Fibrosis

Sameer Desai, Sophia Shen, Zosia Gryz, Elizabeth D. Tullis, Anne L. Stephenson, Bradley S. Quon

CHEST Pulmonary20252 citationsOpen Access

DOI: 10.1016/j.chpulm.2025.100163 PMID: 42548399

Association between Cystic Fibrosis and Pericardial Calcification Detected at Chest CT in Adults.

Rodriguez-Takeuchi S, Tullis E, Babaei Jandaghi A, Yan AT, Colak E, Hall DA, Wong K, Jiménez-Juan L, McIntyre K, Sykes J, Deva DP, Callejas MF

Radiology2025

DOI: 10.1148/radiol.241793 PMID: 39998371

Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.

West NE, Konstan MW, Flume PA, VanDevanter DR, Magaret A, Mazurek H, Amelina EL, Laki I, Chiron R, Sutharsan S, Columbo C, Dorkin HL, Downey DG, Sole A, Hjelte L, Tullis E, Dgetluck N, Dinh Q, Constantine S, White B, Elborn JS, Chmiel JF, JBT101-CF-002 Study Group

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2025

DOI: 10.1016/j.jcf.2025.03.015 PMID: 40425421

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A, VX20-121-102 Study Group, VX20-121-103 Study Group

The Lancet. Respiratory medicine2025

DOI: 10.1016/s2213-2600(24)00411-9 PMID: 39756424

A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.

Waters V, Shaw M, Perrem L, Quon BS, Tullis E, Solomon M, Rayment JH, Lavoie A, Tse SM, Daigneault P, Bilodeau L, Price A, Nicholson M, Chin M, Parkins M, McKinney ML, Tam JS, Stanojevic S, Grasemann H, Ratjen F, (PIPE Study Investigators)

The European respiratory journal202416 citations

DOI: 10.1183/13993003.02278-2023 PMID: 38697648

Longitudinal changes in BMD in adults with cystic fibrosis.

Jad R, Ma X, Stanojevic S, Illango A, Tullis E, Gilmour J, Goss CH, Strug LJ, Stephenson AL

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research202416 citationsOpen Access

DOI: 10.1093/jbmr/zjae139 PMID: 39221749

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Elizabeth Tullis

Research

Latest papers

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and&#xa0;real-world study.

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Exploring the effects of pulmonary rehabilitation and its determinants in lung transplant candidates with cystic fibrosis.

A Multicenter Retrospective Study Evaluating IL-5-Targeted Biologic Therapies for the Treatment of Asthma and Allergic Bronchopulmonary Aspergillosis in Adults With Cystic Fibrosis

Association between Cystic Fibrosis and Pericardial Calcification Detected at Chest CT in Adults.

Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.

Longitudinal changes in BMD in adults with cystic fibrosis.

Frequent collaborators

Felix Ratjen

Valerie Waters

Anne Stephenson

Tanja Gonska

Sanja Stanojevic

Yvonne Yau

Jenna Sykes

Hartmut Grasemann

Annie Dupuis

Annie Lu

Cecilia Chaparro

Jonathan Rayment

Larissa Matukas

Melinda Solomon

Anju Anand

Christopher Yao

Paul Pencharz

Lisa Strug

Julian Tam

Michael Parkins

Wendy Ungar

Lianne Singer

Denise Guerriere

Peter Coyte

Perry Choi

Errol Colak

Edward Etchells

Dawn Pearce

Jackie Chiang

William Weiser

Julie Gilmour

Coleman Rotstein

Kieran McIntyre

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.